Svenskt inhalator vaccin ICOone.
A Swedish company is currently developing a COVID-19 vaccine that can be self-administered with an inhaler, which could make it an easier and cheaper alternative to currently approved jabs.
By using an inhaler, the vaccine will directly reach the lungs and will activate the immune system’s defense, Iconovo said in a statement.
Unlike current vaccines on the market that use RNA or DNA that code for these proteins – such as Pfizer, Moderna, and AstraZeneca – the inhaler uses manufactured COVID-19 proteins.
ISR’s CEO Ola Winqvist further explained the benefits of having two dosage forms in a recent press release:
-"We have chosen to develop two dosage forms to evaluate which route of administration provides the optimal immune response and the best protection against infection. Administration of vaccines via the respiratory tract is so far relatively new and knowledge is needed to determine the best route for activating the immune system. By broadening the collaboration with Iconovo AB, we are investing in knowledge and time to be able to clinically provide a simple vaccine as quickly as possible for countries where cold chains are not secured"
Many benefits of inhalable vaccines
An inhaled dry powdered vaccine, like the one ISR develops, has many advantages over a liquid-based one, including being user-friendly, not requiring refrigerated storage and being cheaper to transport. In addition, there are also clinical benefits of a dry powder vaccine; it reaches the affected area of the lung tissue directly, and it does not require needle jabs with the risk of transmission of blood-borne viruses.
Promising results in an animal model
Earlier this year, ISR completed a provocation study with SARS-CoV-2 in mice transgenic for the ACE2 receptor, and results showed that the mice that were administered two doses of the vaccine in the respiratory tract were fully protected against the virus. With this positive outcome behind it, the company moved on to the next phase of vaccine development, which is now under joint management with Iconovo, which has strong patent protection for ICOone in Europe and India and with several patent applications under consideration in China, the US and Japan.
There are several benefits to administering a vaccine directly into the nasal mucosa. It mimics how many viruses often enter the body and can therefore more effectively trigger the immune defence at the point of entry,” says researcher Karin Norling at the Department of Biology and Biological Engineering at Chalmers University of Technology.
https://israb.se/
https://israb.se/pressdetalj/?id=https://publish.ne.cision.com/v2.0/Release/GetDetail/CBEA9D935C220160
https://iconovo.se/iconovo-and-isr-develop-new-covid-19-inhalation-vaccine/
https://iconovo.se/category/news/
https://english.alarabiya.net/coronavirus/2021/07/26/COVID-19-vaccine-inhaler-Swedish-company-working-on-easy-cheaper-alternative
https://www.chalmers.se/en/departments/physics/news/Pages/Nasal_spray_could_deliver_a_future_mRNA_vaccine_ag ainst_COVID_19.aspx[/quote]
https://www.alpcot.se/StockDetails?insref=3643656&isin=SE0010868943&name =Iconovo&tradecurrency=SEK
Finland.
Citat:
”Vi är nu inne i en väldigt intensiv fas för färdigställandet av vårt vaccin mot SARS-CoV-2, där vi nu i samarbete med experter för inhalationsläkemedel fastställer distribution och leverans av vaccinet. Arbetet pågår nu för fullt för att slutföra och sammanställa data inför ansökan till regulatorisk myndighet för att få genomföra klinisk studie”
kommenterar Ola Winqvist VD, ISR.
kommenterar Ola Winqvist VD, ISR.
A Swedish company is currently developing a COVID-19 vaccine that can be self-administered with an inhaler, which could make it an easier and cheaper alternative to currently approved jabs.
By using an inhaler, the vaccine will directly reach the lungs and will activate the immune system’s defense, Iconovo said in a statement.
Unlike current vaccines on the market that use RNA or DNA that code for these proteins – such as Pfizer, Moderna, and AstraZeneca – the inhaler uses manufactured COVID-19 proteins.
ISR’s CEO Ola Winqvist further explained the benefits of having two dosage forms in a recent press release:
-"We have chosen to develop two dosage forms to evaluate which route of administration provides the optimal immune response and the best protection against infection. Administration of vaccines via the respiratory tract is so far relatively new and knowledge is needed to determine the best route for activating the immune system. By broadening the collaboration with Iconovo AB, we are investing in knowledge and time to be able to clinically provide a simple vaccine as quickly as possible for countries where cold chains are not secured"
Many benefits of inhalable vaccines
Citat:
there are also clinical benefits of a dry powder vaccine; it reaches the affected area of the lung tissue directly, and it does not require needle jabs with the risk of transmission of blood-borne viruses.
An inhaled dry powdered vaccine, like the one ISR develops, has many advantages over a liquid-based one, including being user-friendly, not requiring refrigerated storage and being cheaper to transport. In addition, there are also clinical benefits of a dry powder vaccine; it reaches the affected area of the lung tissue directly, and it does not require needle jabs with the risk of transmission of blood-borne viruses.
Promising results in an animal model
Earlier this year, ISR completed a provocation study with SARS-CoV-2 in mice transgenic for the ACE2 receptor, and results showed that the mice that were administered two doses of the vaccine in the respiratory tract were fully protected against the virus. With this positive outcome behind it, the company moved on to the next phase of vaccine development, which is now under joint management with Iconovo, which has strong patent protection for ICOone in Europe and India and with several patent applications under consideration in China, the US and Japan.
There are several benefits to administering a vaccine directly into the nasal mucosa. It mimics how many viruses often enter the body and can therefore more effectively trigger the immune defence at the point of entry,” says researcher Karin Norling at the Department of Biology and Biological Engineering at Chalmers University of Technology.
https://israb.se/
https://israb.se/pressdetalj/?id=https://publish.ne.cision.com/v2.0/Release/GetDetail/CBEA9D935C220160
https://iconovo.se/iconovo-and-isr-develop-new-covid-19-inhalation-vaccine/
https://iconovo.se/category/news/
https://english.alarabiya.net/coronavirus/2021/07/26/COVID-19-vaccine-inhaler-Swedish-company-working-on-easy-cheaper-alternative
https://www.chalmers.se/en/departments/physics/news/Pages/Nasal_spray_could_deliver_a_future_mRNA_vaccine_ag ainst_COVID_19.aspx[/quote]
https://www.alpcot.se/StockDetails?insref=3643656&isin=SE0010868943&name =Iconovo&tradecurrency=SEK
Citat:
Iconovo AB (publ), som utvecklar kompletta inhalationsprodukter för en global marknad, tillkännagav i dag att de har tecknat ett avtal med immunterapibolaget Immune System Regulation AB (ISR), ett dotterbolag till ISR Immune System Regulation Holding AB (publ), för utveckling av ett inhalerat vaccin mot covid-19 med Iconovos inhalator ICOone. Avtalet är Iconovos andra avtal inom det nya strategiska området för innovativa inhalationsprojekt och bekräftar lämpligheten att använda ICOone även för vacciner.
Avtalet ger ISR en exklusiv global rättighet att använda ICOone för behandling av covid-19 och dess varianter med en teknologi baserad på s.k. spike-proteiner med adjuvans. Iconovo kommer dessutom att kontraktsutveckla en inhalationsprodukt med målet att denna produkt kan testas i en klinisk studie i människa, med beräknad start under andra halvåret 2021. I avtalet får ISR också en framtida option på att använda sin vaccinationsteknologi i ICOone inom influensa, RS-virus och nya covid-virus vacciner baserade på samma teknologi.
https://news.cision.com/se/iconovo/r/iconovo-tecknar-avtal-med-isr-for-utveckling-av-inhalerat-covid-19-vaccin,c3318727
Avtalet ger ISR en exklusiv global rättighet att använda ICOone för behandling av covid-19 och dess varianter med en teknologi baserad på s.k. spike-proteiner med adjuvans. Iconovo kommer dessutom att kontraktsutveckla en inhalationsprodukt med målet att denna produkt kan testas i en klinisk studie i människa, med beräknad start under andra halvåret 2021. I avtalet får ISR också en framtida option på att använda sin vaccinationsteknologi i ICOone inom influensa, RS-virus och nya covid-virus vacciner baserade på samma teknologi.
https://news.cision.com/se/iconovo/r/iconovo-tecknar-avtal-med-isr-for-utveckling-av-inhalerat-covid-19-vaccin,c3318727
Finland.
Citat:
Finländskt vaccin ska stoppa coronaviruset helt och hållet hos de som vaccineras – börjar troligen testas på människor i början av sommaren
Det som är speciellt med det finländska coronavaccinet är att det ska tas i form av en nässpray och inte via en injektion med nål. Vaccinet har redan visat sig fungera väl i djurförsök, uppger forskarna själva.
Säger Kalle Saksela som är professor i virologi vid Helsingfors universitet och leder utvecklingen av det här vaccinet.
Han betonar ändå att den främsta orsaken till att det ser ut att vara en bra idé att ta coronavaccin via näsan är immunologisk.
https://svenska.yle.fi/artikel/2021/02/16/finlandskt-vaccin-ska-stoppa-coronaviruset-helt-och-hallet-hos-de-som-vaccineras
Det som är speciellt med det finländska coronavaccinet är att det ska tas i form av en nässpray och inte via en injektion med nål. Vaccinet har redan visat sig fungera väl i djurförsök, uppger forskarna själva.
Citat:
"Många kan säkert tycka att det är skönt att inte behöva bli stucken med en nål, och så är det också behändigt att man inte behöver sjukvårdspersonal för att kunna ge vaccinet"
Säger Kalle Saksela som är professor i virologi vid Helsingfors universitet och leder utvecklingen av det här vaccinet.
Han betonar ändå att den främsta orsaken till att det ser ut att vara en bra idé att ta coronavaccin via näsan är immunologisk.
Citat:
"Det kan då skapas skydd mot viruset i slemhinnorna, med betoning på de övre luftvägarna och näsan" påpekar han.
https://svenska.yle.fi/artikel/2021/02/16/finlandskt-vaccin-ska-stoppa-coronaviruset-helt-och-hallet-hos-de-som-vaccineras
__________________
Senast redigerad av snuttis 2021-08-02 kl. 10:06.
Senast redigerad av snuttis 2021-08-02 kl. 10:06.